Trending...
- Bob Holz New Video with Darryl Jones of the Rolling Stones, Concert, Album and Endorsement
- Immediate Therapy for Urinary Incontinence in Women
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ryvyl Inc. with Losses of $100,000 to Contact the Firm
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD and was selected for this most competitive showcase for emerging ophthalmology and retina therapeutics and devices.
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- California: Governor Newsom Honors Two CHP Officers With Medal of Valor
- California: Governor Newsom Names Sean Duryee CHP Commissioner
- California: Governor Newsom Calls Out Big Oil on Continued Push for Drilling in Neighborhoods
- City of Long Beach to Provide Sanitation and Water Filling Services to People Living in Recreational Vehicles
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Atlassian Corporation with Losses of $100,000 to Contact the Firm
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Source: Citrus Therapeutics
Filed Under: Medical
0 Comments
Latest on The Californer
- The estate of Shirley Baskin, co-founder of Baskin Robbins, is part of Andrew Jones' Feb. 22 auction
- Presto to Report Second Quarter 2023 Financial Results on February 14, 2023
- San Jose: City to Add Foster Youth Housing
- Bosco Tech to Host Internationally Acclaimed Educational Expert Dr. Michael G. Thompson on Feb. 27
- Governor Newsom Announces Designation of Three More California Jurisdictions as Prohousing for Strides Made to Accelerate Housing Production
- SEW Acquires 3Insys - Provider of an Agile iPaaS Integration Platform for the Energy and Utility industry
- Avirmax Biopharma Inc. Will Present at Glaucoma 360 New Horizons Forum 2023
- Max Verstappen Signs With EA Sports™
- Juicefly Offers High-Quality Vape Products in Los Angeles
- Flexiv Launches Revolutionary Force-Controlled Parallel Robot
- For the Tenth Consecutive Year, Persistent Ranked a Leader in Zinnov Zones Engineering Research and Development Services Ratings USA - English USA - English
- How moving online helped us scale regional meetups
- Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Honda Motor Co., Ltd.
- ATEN Technology Empowers BYOD Collaboration with New Presentation Switches
- SET Announces Groundbreaking Solar Boost Technology
- Soft Treats That Older Dogs Can Sink Their Teeth Into
- California: Governor Newsom Announces Appointments 2.2.23
- The 10 Principles Of Economics And How They Can Benefit You
- HVAC Alliance Expert Offers Reliable Central Heating System Installation Across California and New York
- California: Governor Newsom on Fifth Circuit Court Ruling Allowing Domestic Violence Abusers to Possess Guns